Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

被引：6

作者：

Campelo, Rosario Garcia

Rodriguez, Oscar Gerardo Arrieta

Massuti, Bartomeu

Rodriguez-Abreu, Delvys

Granados, Ana Laura Ortega

Majem, Margarita

Vicente, David

Lianes, Pilar

Bosch-Barrera, Joaquim

Insa, Amelia

Domine, Manuel

Reguart, Noemi

Guirado, Maria

Sala, Maria Angeles

Vazquez-Estevez, Sergio

Caro, Reyes Bernabe

Drozdowskyj, Ana

Verdu, Ana

Karachaliou, Niki

Rosell, Rafael

机构：

[1] Univ Hosp A Coruna XXIAC SERGAS, Med Oncol Serv, La Coruna, Spain

[2] Inst Nacl Cancerol INCan, Mexico City, DF, Mexico

[3] Alicante Univ Hosp ISABIAL, Alicante, Spain

[4] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

[5] Complejo Hosp Jaen, Med Oncol, Jaen, Spain

[6] Hosp Santa Creu i St Pau, Barcelona, Spain

[7] Hosp Univ Virgen Macarena, Seville, Spain

[8] Hosp Mataro, Mataro, Spain

[9] Hosp Univ Girona Dr Josep Trueta, Girona, Spain

[10] Hosp Clin Univ Valencia, Valencia, Spain

[11] Univ Hosp Fdn Jimenez Diaz, Oncol Dept, Madrid, Spain

[12] Univ Hosp Fdn Jimenez Diaz, Translat Oncol Div, Madrid, Spain

[13] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[14] Hosp Gen Elche, Alicante, Spain

[15] Univ Hosp Basurto, Bilbao, Spain

[16] Lucus Augusti Univ Hosp, Lugo, Spain

[17] Hosp Virgen Del Rocio, Seville, Spain

[18] Pivotal, Madrid, Spain

[19] Spanish Lung Canc Grp Off, Barcelona, Spain

[20] Hosp Univ Sagrat Cor, Grp Quironsalud, Oncol Dept, Barcelona, Spain

[21] Catalan Inst Oncol, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9012

引用

页数：1